)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Carisma Therapeutics (CARM) investor relations material
Carisma Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary27 Aug, 2025
Executive summary
Operations reduced to focus on strategic alternatives and wind down, with no intention to resume R&D activities; 84% workforce reduction executed in March 2025.
Entered into a merger agreement with OrthoCellix; post-merger, legacy shareholders expected to own 10% of the combined company.
Nasdaq compliance issues persist; reverse stock split approved to help maintain listing, but continued listing is uncertain.
Collaboration with Moderna concluded for R&D funding; future revenue depends on milestones and royalties.
Financial highlights
Net loss of $9.8M for Q2 2025, improved from $11.2M in Q2 2024; six-month net loss of $19.0M, down from $30.1M year-over-year.
Q2 2025 collaboration revenue was $0, down from $9.2M in Q2 2024; six-month revenue was $3.7M, down from $12.6M year-over-year.
Cash and cash equivalents at June 30, 2025 were $2.0M, with an accumulated deficit of $324.6M.
Research and development expenses dropped to $2.4M in Q2 2025 from $15.3M in Q2 2024; general and administrative expenses fell to $3.4M from $5.6M.
Losses of $3.5M on sale of held-for-sale assets and $0.9M on lease abandonment recognized in Q2 2025.
Outlook and guidance
Cash runway expected to last into fall 2025; substantial doubt exists about ability to continue as a going concern beyond one year.
Future operations are highly dependent on successful completion of the OrthoCellix Merger; failure may lead to bankruptcy or liquidation.
No plans to resume historical R&D activities unless a strategic transaction or significant funding is secured.
How does net cash impact Carisma's merger valuation?
What if OrthoCellix merger does not close?
What is the value of Moderna's option rights?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Carisma Therapeutics earnings date
Q3 20257 Nov, 2025
Next Carisma Therapeutics earnings date
Q3 20257 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies using its proprietary macrophage and monocyte cell engineering platform. The company's primary aim is to create treatments for cancer and other serious diseases by leveraging engineered macrophages and monocytes to attack and eliminate tumor cells. Carisma's product candidates include ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) and CAR-macrophage (CAR-Macrophage) cellular therapies designed to treat solid tumors that overexpress specific markers such as HER2. The company is headquartered in Philadelphia, PA, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage